Researchers at Michigan Medicine have uncovered that sotagliflozin, an FDA-approved diabetes medication, reduces the risk of heart attack and stroke.
New study uncovers why sotagliflozin may lower risk of heart attack and stroke For millions living with type 2 diabetes, heart disease remains one of the greatest threats to their health. Researchers at Michigan Medicine have uncovered a mechanism that may explain why sotagliflozin, an FDA-approved diabetes medication marketed as Inpefa, reduces the risk of